Louis Gerard 4.25K Followers
Summary
I upgrade Lumentum to Hold: the nearly 35% decline and stronger growth have corrected the prior overvaluation.
LITE is effectively a Marvell proxy, trading 16.5% below deal value under a fixed 4.5-share exchange ratio.
Q1 revenue grew 136% year over year, while systems diversification and component orders extending into early 2029 challenge my earlier thesis.
Chinese regulatory review, rising competing capacity, weak cash conversion and convertible debt remain risks; margin normalization persists if the deal fails.
JHVEPhoto/iStock Editorial via Getty Images
Introduction
It has been over 2 months and a half since I last covered Lumentum (LITE) and gave it a Sell rating based mainly on one idea, that the margins were a shortage
This article was written by
Louis Gerard 4.25K Followers
As a detail-oriented investor with a strong foundation in finance and business writing, I focus on analyzing undervalued and disliked companies or industries that have strong…